Singapore, June 1 -- China-based Innovent Biologics and American firm Pfizer Inc. have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines.

The partnership includes licensing, co-development, and co-commercialisation opportunities across a diverse portfolio of antibody-drug conjugates (ADCs) with novel differentiated payloads and multi-specific antibodies with differentiated immune-engaging features and unique designs.

The strategic collaboration brings together Innovent's scientific discovery and clinical capabilities in oncology innovation with Pfizer's deep scientific expertise, global clinical development capa...